Finnish biopharmaceutical company Desentum closes financial round totalling nearly EUR 2 Million

Desentum, a company developing novel allergen immunotherapy – aka allergy vaccine – secured funding to advance their treatment targeting birch pollen allergy. ESPOO, Finland, 23 January 2017– Today, Desentum, a biopharmaceutical company developing next generation immunotherapy to fight allergies, announced that it has completed a Series A financing round totalling approximately EUR 2 Million. The participating investors include Belgian Cascara Ventures, Luxembourgian ACME Investments, Finnish VTT Ventures and Sto-Rahoitus, and the founding shareholders. Desentum will use most of the